Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Recruiting · NCT07104565 · Registry updated 2026-09-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 2 | 2026-09-14 | NCT07104565 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Incyte Corporation | 153 |
39 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.